Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 1, 2023
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
Matthew Caufield Reiterated (ALDX) at Strong Buy and Held Target at $15 on, Mar 1st, 2023
Matthew Caufield of HC Wainwright & Co., Reiterated "Aldeyra Therapeutics, Inc." (ALDX) at Strong Buy and Held Target at $15 on, Mar 1st, 2023.
Matthew has made no other calls on ALDX in the last 4 months.
There is 1 other peer that has a rating on ALDX. Out of the 1 peers that are also analyzing ALDX, 0 agree with Matthew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Matthew
- Yigal Nochomovitz of "Citigroup" Maintained at Strong Buy with Decreased Target to $23 on, Monday, November 21st, 2022
